Noyada (captopril)
pCPA File Number:
23268
Negotiation Status:
Concluded with an LOI
Indication(s):
• for the treatment of essential or renovascular hypertension
• for the treatment of congestive heart failure
• to improve survival, delay the onset of symptomatic heart failure and reduce hospitalizations for heart failure following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of ≤ 40%.
• for the treatment of diabetic nephropathy (proteinuria ≥ 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy.
• for the treatment of congestive heart failure
• to improve survival, delay the onset of symptomatic heart failure and reduce hospitalizations for heart failure following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of ≤ 40%.
• for the treatment of diabetic nephropathy (proteinuria ≥ 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy.
Sponsor/Manufacturer:
Ethypharm Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: